MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor, together with Longitude Capital. Existing investors include US Venture Partners (USVP), Osage University Partners, Action Potential Venture Capital, GPG Ventures, The Vertical Group and Exceller Hunt Ventures.
Vivistim is the first and only FDA-approved intervention clinically proven to help chronic ischemic stroke survivors regain 2-3 times more upper extremity function than high-intensity stroke therapy alone. Approved with the Breakthrough Device Designation, Vivistim is an implanted device that a therapist pairs with vagus nerve stimulation (VNS) during high-repetition, goal-oriented therapy tasks. This Paired VNS Therapy helps increase neuroplasticity so stroke survivors can make unprecedented gains with their hands and arms during activities of daily living.
Real-world data presented at the 2025 International Stroke Conference by two independent comprehensive stroke centers complements the published clinical studies proving the effectiveness of Paired VNS Therapy for chronic stroke survivors.
“We’ve built programs in 20% of Joint Commission Comprehensive Stroke Centers and 50% of Becker’s 2024 100 Great Neuro and Spine Programs by presenting Vivistim as the evidence-based chronic stroke recovery solution that’s been missing from the stroke continuum of care,” said Richard Foust, MicroTransponder’s CEO. “In partnership with leading healthcare providers, we’ve helped build new programs that support our goal of changing the standard of care for stroke treatment across the US, renewing hope for stroke survivors and their caregivers.”
Vivistim’s rapid adoption is a testament to the collaborative approach between MicroTransponder and the hospital systems and clinics that recognize the need for an evidence-based chronic stroke intervention. These partnerships leverage robust education, awareness, and referral initiatives to seamlessly connect stroke survivors to implanting surgeons and Paired VNS Therapy providers.
To join the movement and get started with a Vivistim Paired VNS Therapy program for chronic stroke recovery, visit www.vivistim.com. Tap to review the clinical bibliography and safety information.
About MicroTransponder®, Inc.
MicroTransponder®, Inc. is a privately held, global medical device company based in Austin, Texas, committed to developing research-based neuroscience solutions. The company focuses on restoring dignity and function for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder’s FDA-approved Vivistim® Paired VNS™ System is a first-of-its-kind, clinically proven medical device that generates two to three times more improvement in upper limb function for chronic stroke survivors after six weeks of in-clinic occupational or physical therapy. For more information, visit www.vivistim.com and review safety information at www.vivistim.com/safety.
About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.
